Dr. Duval on the Use of MSI-H as a Biomarker of Response in Patients With Cancer


Alex Duval, MD, PhD, discusses the use of microsatellite instability–high as a biomarker of response to therapy in patients with cancer.

Alex Duval, MD, PhD, professor of molecular oncology, director, Instability of Microsatellites and Cancer team, Saint-Antoine Research Center, French Institute of Health and Medical Research, discusses the use of microsatellite instability–high (MSI-H) as a biomarker of response to therapy in patients with cancer.

​As a biomarker of response, MSI-H can influence ​and guide clinical treatment decisions, says Duval. Moreover, MSI status may be the first indication that giving immunotherapy with checkpoint inhibitors is warranted in a particular patient.

Currently, using MSI status to inform immunotherapy initiation is commonly used in the metastatic setting. However, this concept will likely be applied to the non-metastatic to inform response other drugs such as chemotherapy.

Notably, this applies to a host of therapies, including chemotherapy. For example, it is now understood that patients ​with gastric cancer who are MSI-H will not ​respond to chemotherapy, Duval concludes.

Related Videos
Naval G. Daver, MD
Pasi A. Jänne, MD, PhD
Saad Z. Usmani, MD, MBA, FACP
J. Randolph (Randy) Hecht, MD
Alessandro Di Federico, MD
Qian (Janie) Qin, MD
Judy C. Boughey, MD
Tian Zhang, MD, MHS
Francisco J. Esteva, MD, PhD
Related Content